375 results
Page 3 of 19
424B5
xn61ruvg5e
3 Dec 21
Prospectus supplement for primary offering
4:06pm
424B5
71rzfkg
30 Nov 21
Prospectus supplement for primary offering
5:12pm
8-K
EX-99.1
twy1gsp5ov9nznoyb
30 Nov 21
ImmunoGen Announces Positive Top-Line Results from Pivotal SORAYA Trial of Mirvetuximab Soravtansine in Ovarian Cancer
6:37am
8-K
EX-99.1
vlyi8
29 Oct 21
ImmunoGen Reports Recent Progress and Third Quarter 2021 Financial Results
6:43am
424B5
iga9sc46y q623e0r
12 Aug 21
Prospectus supplement for primary offering
10:11am
8-K
EX-99.1
zjnvvkx
30 Jul 21
ImmunoGen Reports Recent Progress and Second Quarter 2021 Financial Results
6:36am
DEFA14A
p6e1dpnov00zgrt5
26 May 21
Additional proxy soliciting materials
4:24pm
8-K
EX-99.1
qpiuj yzhrg2
10 May 21
ImmunoGen Reports Recent Progress and First Quarter 2021 Financial Results
6:36am
8-K
EX-99.1
gvncsrh q1
12 Feb 21
Top-Line Data from Pivotal SORAYA Trial for Mirvetuximab Soravtansine in Ovarian Cancer Expected in Q3 2021; BLA to be Submitted by Year-End
6:37am
8-K
EX-10.1
esyeq94 spe9h4661p
18 Dec 20
Entry into a Material Definitive Agreement
5:19pm
424B5
a5h7q
18 Dec 20
Prospectus supplement for primary offering
5:16pm
S-3ASR
6juo37
18 Dec 20
Automatic shelf registration
4:45pm
8-K
EX-99.1
pt1kh hrvg9q
18 Dec 20
Other Events
4:16pm